Level A· Stronger Clinical EvidenceMeta-analysisEurope PMC

The impact of cell-based therapy on female sexual dysfunction: a systematic review and meta-analysis

Saltzman RG., G Campbell K., J Ripps S., Golan R., Cabreja-Castillo MA., Garzon AM.

Meta-analysis with a reported sample of 29 on Scar, published in Sex Med Rev (2023) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Sex Med Rev (2023)
Reported sample size
29
Source database
Europe PMC
PMID
37279578
PMCID
PMC12017765
DOI
10.1093/sxmrev/qead023
NCT
NCT02065245

Abstract (original English)

Introduction Female sexual dysfunction (FSD) is a complex issue affecting women of all ages; it involves several overlapping body systems and profoundly affects quality of life. The use of cell-based therapy, such as mesenchymal stem cells, has recently been investigated as a potential treatment for FSD. Objectives This systematic review and meta-analysis aim to assess FSD outcomes following cell-based therapy. Methods We evaluated peer-reviewed articles from multiple online databases through November 2022 to identify studies that used cell-based therapy and reported sexual function outcomes in women. We performed a meta-analysis using data pooled from 3 clinical trials at our institution: CRATUS (NCT02065245), ACESO (NCT02886884), and CERES (NCT03059355). All 3 trials collected data from the Sexual Quality of Life-Female (SQOL-F) questionnaire as an exploratory outcome. Results Existing literature on this topic is scarce. Five clinical studies and 1 animal study were included in the systematic review, and only 2 clinical studies were considered good quality: 1 reported significant SQOL-F improvement in women 6 months after cell therapy, and 1 reported posttherapy sexual satisfaction in all women. When individual patient data were pooled in a meta-analysis from 29 women across 3 trials at our institution, the SQOL-F was not significantly improved. Conclusion Despite growing int

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansSexual BehaviorSexual Dysfunctions, PsychologicalQuality of LifeWomen's HealthFemaleSexual Dysfunction, Physiological

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research